Kerry Jenkins

Title: Kerry Jenkins: Innovator in Kinase Inhibitors

Introduction

Kerry Jenkins is a notable inventor based in Slough, GB. She has made significant contributions to the field of medicinal chemistry, particularly in the development of kinase inhibitors. With a total of 2 patents, her work is focused on addressing various medical conditions through innovative chemical compounds.

Latest Patents

Kerry's latest patents include two groundbreaking inventions. The first patent, titled "Fused pyridine derivatives as kinase inhibitors," describes a series of heteroaryl-substituted fused pyridine derivatives. These compounds are selective inhibitors of PO kinase enzymes and are beneficial in treating inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive, or ophthalmic conditions. The second patent, "Fused thiazole derivatives as kinase inhibitors," details a series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives. These compounds, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, serve as selective inhibitors of PI3 kinase enzymes, also aiding in the treatment of similar medical conditions.

Career Highlights

Kerry Jenkins is currently employed at UCB Pharma S.A., where she continues to advance her research in kinase inhibitors. Her work is instrumental in the development of new therapeutic options for patients suffering from various diseases.

Collaborations

Kerry collaborates with talented individuals in her field, including Rikki Peter Alexander and Pavandeep Singh Aujla. These partnerships enhance her research and contribute to the innovative solutions being developed at UCB Pharma.

Conclusion

Kerry Jenkins is a prominent inventor whose work in kinase inhibitors is paving the way for new medical treatments. Her contributions to the field of medicinal chemistry are significant and continue to impact the healthcare industry positively.